|
Uppsala, Sweden, February 13, 2007
Gyros completes five new sales of its
Gyrolab® protein quantification platform
Gyros announced today that it has completed the separate sales
of five Gyrolab® microfluidic system platforms to Merck,
Biogen-Idec and a third, unnamed company, all in the USA, and to
NovImmune and Serono in Europe. |
|
Gyros microfluidic platform consists of Gyrolab Bioaffy® compact
disk (CD) microlaboratories (facilitating miniaturized and
integrated protein quantification applications) and Gyrolab
Workstation (a fully automated system for running Gyrolab Bioaffy
CDs). Together they provide a simple to use, precisely controlled
solution for processing hundreds of samples in parallel at nanoliter
scale. Scientists are able to use immunoassays with a very broad
measurement range to generate more information from less sample,
improving both productivity and efficiency. |
|
Commenting on the recent sales, Gyros CEO, Jan
Würtz, said, “2006 was a successful year for Gyros. Following sales
earlier in 2006 to CAT and AstraZeneca, these five new sales mean
that we are really starting to extend our customer base. We will be
looking to continue this trend through 2007, as more and more
companies recognize that our microfluidic technology can provide
them with significant advantages over traditional methods, like
ELISA.” |
|
About Gyros AB
Gyros is the leader in the
miniaturization and integration of laboratory applications through
its proprietary microfluidics platform, Gyrolab CD (compact disc)
microlaboratory. Gyros delivers simple to use, precisely controlled
solutions for processing hundreds of samples in parallel, generating
more information from less sample and improving lab productivity and
efficiency.
Application-specific microlaboratories use a modular design
offering the potential to run different applications on a single
instrument and to create customized solutions. The company is
currently focused on two market segments: quantitative protein
analysis for research, drug discovery and development applications;
and, in vitro diagnostics for medical applications. Gyros has
50 employees working at its headquarters and European sales office
in Uppsala, Sweden and its sales office in the USA.
For further information, visit www.gyros.com or contact:
Jan
Würtz, President and CEO, Gyros AB
Tel: +46 (0)18 566 400
Mobile: +46 (0)70 592 5670
jan.wurtz@gyros.com
Christina Burtsoff Asp, VP Marketing, Gyros AB
Tel: +46 (0)18
566 404
Mobile: +46 (0)70 666 1642
christina.asp@gyros.com
------------------------------------------------------------------------------------------------
Statements
in this press release that are not strictly historical may be
forward-looking and include risks and uncertainties. Therefore,
though based on Gyros’ current expectations, it should be duly noted
that a variety of factors could cause actual results and experiences
to differ materially from what is herein expressed. Risks and
uncertainties include, but are not limited to, risks associated with
the management of growth and international operations (including
effects of currency fluctuations), variability of operating results,
unforeseen changes in the diagnostic and pharmaceutical markets,
market competition, rapid or unexpected changes in technologies,
fluctuations in product demand, difficulties to successfully
develop, adapt, produce or commercialize products, the ability to
identify and develop new products and to differentiate products from
those of competitors, as well as various legal
hazards.
------------------------------------------------------------------------------------------------
|
